 Oncternal Therapeutics, Inc. Nasdaq: ONCT, a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the presentation of preclinical data from its ROR1 chimeric antigen receptor T cell CAR-T program at the American Society of Clinical Oncology ASCO Society for Immunotherapy of Cancer SITC meeting in Orlando, Florida. A copy of the poster presentation is available online at 